Korea Arlico Pharm Co Ltd
Korea Arlico Pharm has a liquidity position that is relatively stable, with cash and equivalents of KRW 19.3 billion, but its free cash flow is negative at KRW -2.8 billion, indicating that capital expenditures are outpacing operating cash flow. The company's price-to-book ratio of 0.69 suggests that the market values the company at a discount to its book value, which may reflect concerns about its profitability or asset quality. Profitability metrics are weak, with a return on equity of -0.77% and a return on assets of -0.35%, both significantly below the industry median for pharmaceutical firms. The company reported a net loss of KRW 605 million in the latest period, which is a red flag for investors expecting consistent earnings. Operating income of KRW 989 million is also low relative to its revenue of KRW 201.2 billion, indicating that the company is struggling to convert sales into profit. The company's revenue is derived from a mix of pharmaceutical and non-pharmaceutical products, with no specific segment breakdown provided in the input data. However, the geographic exposure is not detailed, and the input does not provide information on revenue concentration by region or product line. This lack of transparency may limit the ability to assess the company's exposure to regional or product-specific risks. Looking ahead, the company's growth trajectory is uncertain. The input data does not provide forward-looking revenue guidance or outlook for the next fiscal year. However, the negative net income and weak operating margins suggest that the company may face challenges in achieving revenue growth or improving profitability in the near term. The risk assessment indicates a medium liquidity risk, with a current ratio of 1.12 and a debt-to-equity ratio of 0.63. The company's long-term debt of KRW 49.0 billion is partially offset by cash and equivalents, but the free cash flow remains negative. The risk of dilution is assessed as low, but the company's net cash position is negative after subtracting total debt, which could signal potential refinancing or capital-raising needs. Recent events or filings are not detailed in the input data, so there is no specific information on recent corporate actions, earnings calls, or regulatory developments. The absence of such data limits the ability to assess the company's recent performance or strategic direction.
Business. Korea Arlico Pharm Co Ltd is a Korea-based company engaged in the manufacturing and sales of medicines, including hyperlipidemia, cerebrovascular disease, digestive, allergy, and respiratory treatments, as well as non-pharmaceutical products such as sun cream, hand cream, and medical devices, with products sold in domestic and overseas markets.
Classification. Korea Arlico Pharm is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry, with a classification confidence of 0.92.
- Korea Arlico Pharm is a diversified healthcare company with a focus on pharmaceuticals and non-pharmaceutical products.
- The company is currently unprofitable, with a net loss and weak return metrics.
- Liquidity is stable but free cash flow is negative, indicating operational inefficiencies.
- The company's debt-to-equity ratio is moderate, but its net cash position is negative after subtracting total debt.
- There is no detailed segment or geographic breakdown of revenue, limiting visibility into the company's exposure to specific markets or products.
- The risk of dilution is low, but the company may need to raise capital to support operations or growth initiatives.
- --
- ## RATIONALES
- Net cash is negative after subtracting total debt.